Troxipide is a drug used in the treatment of gastroesophageal reflux disease. Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum. Troxipide is currently marketed in Japan (Aplace), China (Shuqi), South Korea (Defensa), and India (Troxip). It is used for the management of gastric ulcers, and amelioration of gastric mucosal lesions in acute gastritis and acute exacerbation of chronic gastritis.

Read more about TroxipidePharmacokinetics, Clinical Experience, Safety and Tolerability

Other articles related to "troxipide":

Troxipide - Safety and Tolerability
... In all clinical studies, troxipide was well tolerated ... In a comparative study with ranitidine, troxipide was assessed as a more tolerable medication than ranitidine ... A favorable tolerability profile for troxipide was reported by 95.45% of the investigators as compared to 65.45% for ranitidine while favorable tolerability profile was reported by 93.67% of the patients for troxipide ...